Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Treatments for Dementia and Alzheimer's Disease possible with Chinese medicine
A new study of classical Chinese medical texts identifies references to age-related memory impairment similar to modern-day Alzheimer's disease, and to several plant-based ingredients used centuries ago -- and still in use today -- to treat memory impairment. Experimental studies of five of these traditional Chinese medicines suggest that they have biological activity relevant to Alzheimer's disease, according to an article in The Journal of Alternative and Complementary Medicine, a peer-reviewed publication from Mary Ann Liebert, Inc.
- Read more about The Scripps Research Institute Study Illuminates How Mystery MS Drug Works
A study by scientists at The Scripps Research Institute (TSRI) has helped to de-mystify the molecular workings of the multiple sclerosis (MS) drug Tecfidera®. The drug is the most widely prescribed pill-based therapy for MS, but its biological mechanism remains mysterious.
- Read more about FDA approves Amjevita, a biosimilar to Humira
The U.S. Food and Drug Administration approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases.
- Read more about Geetanjali Institute of Pharmacy organised contemporary approaches for the development of Natural Products and envisaged future trends
A One day National Conference on “Contemporary Approaches for the Development of Natural Products and Envisaged Future Trends” Sponsored by Indian Council of Medical Research (ICMR) and Association of Pharmaceutical Teachers of India (APTI) was recently organized by Geetanjali Institute of Pharmacy, Geetanjali University, Udaipur on 17th September, 2016. Around 400 delegates comprising of Principals, teachers, research scholars, post graduate and graduate students from various institutes across India participated in the one day conference.
- Read more about U.S. FDA Approves Janssen’s INVOKAMET® XR
Janssen Pharmaceuticals, Inc. (Janssen) announced the U.S. Food and Drug Administration (FDA) has approved INVOKAMET® XR—a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release (XR)—for first-line use as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes when treatment with the two medications is appropriate. INVOKAMET® XR combines INVOKANA® (canagliflozin), the most prescribed sodium glucose co-transporter 2 (SGLT2) inhibitor, with more than 9 million U.S. prescriptions since launch, and an XR formulation of metformin. Metformin is commonly prescribed as an initial therapy for the treatment of type 2 diabetes.
- Read more about Takeda, Affilogic collaborate to develop Nanofitin-based therapies in CNS
Takeda Pharmaceutical Company Limited and Affilogic jointly announced that the companies have entered into a research collaboration to explore using Affilogic’s proprietary Nanofitins platform in therapies targeting the central nervous system
- Read more about Lundbeck’s first out of three phase III studies on idalopirdine did not met primary endpoint
H. Lundbeck A/S announced the headline conclusions from the first clinical phase III study, STARSHINE, in the ongoing phase III programme evaluating the efficacy of the investigational drug idalopirdine for the symptomatic treatment of patients with mild to moderate Alzheimer's disease.
- Read more about AstraZeneca withdraw European MAA for cediranib
AstraZeneca announced its decision to withdraw the Marketing Authorisation Application (MAA) submitted to the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in June 2015 for cediranib in combination with platinum-based chemotherapy followed by maintenance monotherapy for the treatment of adult patients with platinum-sensitive relapsed ovarian cancer (including fallopian tube or primary peritoneal sub types).

[adsense:336x280:8701650588]
- Read more about Computational method identifies existing drugs with virus-fighting potential
A new, computer-based screening method could reveal the virus-fighting potential of drugs originally developed to treat other conditions, reports a study in PLOS Computational Biology.
- Read more about US FDA approves Sarepta's Exondys 51 inj
Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics, announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Exondys 51 (eteplirsen) as a once weekly intravenous infusion of 30 milligrams per kilogram for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the DMD gene that is amenable to exon 51 skipping.